Cargando…
The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber
OBJECTIVE: The study objective was to investigate the prophylactic efficacy of montelukast (MLK) 10 mg in suppressing seasonal allergic rhinitis (SAR) symptoms induced by Japanese cedar (JC) pollen and to determine how many days before exposure to JC in the artificial exposure chamber (OHIO chamber)...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980728/ https://www.ncbi.nlm.nih.gov/pubmed/27536427 http://dx.doi.org/10.3109/21556660.2012.728547 |
_version_ | 1782447505036804096 |
---|---|
author | Hashiguchi, Kazuhiro Okubo, Kimihiro Wakabayashi, Ken-ichiro Tanaka, Nobuaki Watada, Yukiko Suematsu, Kiyochika Gotoh, Minoru |
author_facet | Hashiguchi, Kazuhiro Okubo, Kimihiro Wakabayashi, Ken-ichiro Tanaka, Nobuaki Watada, Yukiko Suematsu, Kiyochika Gotoh, Minoru |
author_sort | Hashiguchi, Kazuhiro |
collection | PubMed |
description | OBJECTIVE: The study objective was to investigate the prophylactic efficacy of montelukast (MLK) 10 mg in suppressing seasonal allergic rhinitis (SAR) symptoms induced by Japanese cedar (JC) pollen and to determine how many days before exposure to JC in the artificial exposure chamber (OHIO chamber) would be optimal to start administration. METHODS: This was a single-institution, double-blind, randomized placebo-controlled four-group parallel inter-group comparison study. Adult volunteers with JC pollinosis were divided into four groups: an MLK 7-day administration group (n = 27), an MLK 3-day administration group (n = 27), an MLK 1-day administration group (n = 26), and a placebo group (n = 26). The mean change in total nasal symptom scores (nasal obstruction, nasal discharge and sneezing) (TNSS) and each of the nasal symptom scores during exposure of JC pollen in the OHIO chamber were investigated. RESULTS: The mean change in TNSS was significantly lower in the MLK treatment group, regardless of the number of days of administration, than in the placebo group (p = 0.0192). The results for the individual nasal symptoms showed that nasal obstruction was significantly suppressed in the 1-day administration group as compared with placebo (p = 0.0076), but no differences were found in sneezing score between any of the groups. For nasal discharge, we found a trend towards the effect clearing up after 3 days of administration. No serious adverse events were observed during the study. CONCLUSION: Although this study was acute and this artificial exposure model was conducted out of the pollen season, nasal symptoms that developed in the pollen exposure chamber, especially nasal obstruction, were significantly suppressed by starting oral administration of MLK 10 mg at least 1 day before exposure. These results suggest that prophylactic administration of MLK is effective and safe in the treatment of SAR. |
format | Online Article Text |
id | pubmed-4980728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-49807282016-08-17 The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber Hashiguchi, Kazuhiro Okubo, Kimihiro Wakabayashi, Ken-ichiro Tanaka, Nobuaki Watada, Yukiko Suematsu, Kiyochika Gotoh, Minoru J Drug Assess Original Articles OBJECTIVE: The study objective was to investigate the prophylactic efficacy of montelukast (MLK) 10 mg in suppressing seasonal allergic rhinitis (SAR) symptoms induced by Japanese cedar (JC) pollen and to determine how many days before exposure to JC in the artificial exposure chamber (OHIO chamber) would be optimal to start administration. METHODS: This was a single-institution, double-blind, randomized placebo-controlled four-group parallel inter-group comparison study. Adult volunteers with JC pollinosis were divided into four groups: an MLK 7-day administration group (n = 27), an MLK 3-day administration group (n = 27), an MLK 1-day administration group (n = 26), and a placebo group (n = 26). The mean change in total nasal symptom scores (nasal obstruction, nasal discharge and sneezing) (TNSS) and each of the nasal symptom scores during exposure of JC pollen in the OHIO chamber were investigated. RESULTS: The mean change in TNSS was significantly lower in the MLK treatment group, regardless of the number of days of administration, than in the placebo group (p = 0.0192). The results for the individual nasal symptoms showed that nasal obstruction was significantly suppressed in the 1-day administration group as compared with placebo (p = 0.0076), but no differences were found in sneezing score between any of the groups. For nasal discharge, we found a trend towards the effect clearing up after 3 days of administration. No serious adverse events were observed during the study. CONCLUSION: Although this study was acute and this artificial exposure model was conducted out of the pollen season, nasal symptoms that developed in the pollen exposure chamber, especially nasal obstruction, were significantly suppressed by starting oral administration of MLK 10 mg at least 1 day before exposure. These results suggest that prophylactic administration of MLK is effective and safe in the treatment of SAR. Taylor & Francis 2012-10-09 /pmc/articles/PMC4980728/ /pubmed/27536427 http://dx.doi.org/10.3109/21556660.2012.728547 Text en © 2012 The Author(s). Published by Taylor & Francis http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Original Articles Hashiguchi, Kazuhiro Okubo, Kimihiro Wakabayashi, Ken-ichiro Tanaka, Nobuaki Watada, Yukiko Suematsu, Kiyochika Gotoh, Minoru The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber |
title | The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber |
title_full | The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber |
title_fullStr | The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber |
title_full_unstemmed | The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber |
title_short | The assessment of the optimal duration of early intervention with montelukast in the treatment of Japanese cedar pollinosis symptoms induced in an artificial exposure chamber |
title_sort | assessment of the optimal duration of early intervention with montelukast in the treatment of japanese cedar pollinosis symptoms induced in an artificial exposure chamber |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980728/ https://www.ncbi.nlm.nih.gov/pubmed/27536427 http://dx.doi.org/10.3109/21556660.2012.728547 |
work_keys_str_mv | AT hashiguchikazuhiro theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT okubokimihiro theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT wakabayashikenichiro theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT tanakanobuaki theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT watadayukiko theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT suematsukiyochika theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT gotohminoru theassessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT hashiguchikazuhiro assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT okubokimihiro assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT wakabayashikenichiro assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT tanakanobuaki assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT watadayukiko assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT suematsukiyochika assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber AT gotohminoru assessmentoftheoptimaldurationofearlyinterventionwithmontelukastinthetreatmentofjapanesecedarpollinosissymptomsinducedinanartificialexposurechamber |